SANASana Biotechnology, Inc.
$2.33-58% 1Y
$2.33
$2.2852 weeks$5.59
SANA as reported
- Net income
- −$212M
Net income · −16% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$135M
Free cash flow · −27% year on year · trailing twelve months to Q2 2026
- EPS
- −$0.76
EPS · −28% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$212M | −16% | Q2 2026 |
| EPS | −$0.76 | −28% | Q2 2026 |
| ROE | −153% | n/a | Q2 2026 |
| ROA | −57% | n/a | Q2 2026 |
| Free cash flow | −$135M | −27% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Sana Biotechnology, Inc. (SANA) · Net incomeNet incomeSana Biotechnology, Inc. (SANA)